Comprehensive Analysis of the Prognosis and Immune Infiltration for CXC Chemokines in Colorectal Cancer

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Jul 7

PMID 34233297

Citations 8

Authors

Xi Yang

Yuanfeng Wei

Feng Sheng

Yirong Xu

Jiao Liu

Ling Gao

Ju Yang

Xinchen Sun

Junxing Huang

Qing Guo

Affiliations

Soon will be listed here.

Abstract

The C-X-C motif (CXC) chemokines are a family of chemotactic molecules that have been identified as potential prognostic markers and prospective therapeutic targets for many kinds of cancer types. Increasing evidence shows that CXC chemokines are associated with the progression of colorectal cancer (CRC); however, the correlations of CXC chemokines with prognostic and immune infiltrates in CRC remain to be clarified. In this study, we analyzed the mRNA expression level, prognostic data and immune infiltrates of CXC chemokines in CRC patients from the Gene Expression Profiling Interactive Analysis, Oncomine, cBioPortal and databases using GeneMANIA, STRING, DAVID 6.8, and TIMER. Our results showed that CXCL1/2/3/4/5/8/9/10/11/13/14/16 were significantly overexpressed in CRC tissues. Furthermore, expression of CXCL1/2/3/9/10/11 was associated with tumor stage in CRC. A significant association was also identified between the co-expression of CXCL16 with EGFR, KRAS and NRAS. In addition, the survival analysis suggested that high CXCL2/3/8/9/10/11/14 expression is correlated with clinical outcomes of CRC patients. Moreover, a significant association was observed between the CXCL8/9/10/11 expression and immune infiltration in colonic and rectal adenocarcinoma. Overall, CXC chemokines are not only implicated as prognostic biomarkers for CRC patients, but may also influence the immune status of CRC tissues.

Citing Articles

NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis.

Xing C, Zhao L, Zou W, Peng X, Xing X, Li J Sci Rep. 2025; 15(1):4300.

PMID: 39905237 PMC: 11794712. DOI: 10.1038/s41598-025-88966-6.

RSAD2, a pyroptosis-related gene, predicts the prognosis and immunotherapy response for colorectal cancer.

Li Y, Cui Q, Zhou B, Zhang J, Guo R, Wang Y Am J Cancer Res. 2024; 14(5):2507-2522.

PMID: 38859852 PMC: 11162672. DOI: 10.62347/RGJO6884.

Macrophage Inflammatory Proteins (MIPs) Contribute to Malignant Potential of Colorectal Polyps and Modulate Likelihood of Cancerization Associated with Standard Risk Factors.

Wierzbicki J, Bednarz-Misa I, Lewandowski L, Lipinski A, Klopot A, Neubauer K Int J Mol Sci. 2024; 25(3).

PMID: 38338661 PMC: 10855842. DOI: 10.3390/ijms25031383.

CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer.

Zajkowska M, Dulewicz M, Kulczynska-Przybik A, Safiejko K, Juchimiuk M, Konopko M Sci Rep. 2023; 13(1):17688.

PMID: 37848726 PMC: 10582048. DOI: 10.1038/s41598-023-45093-4.

The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers.

Korbecki J, Bosiacki M, Barczak K, Lagocka R, Chlubek D, Baranowska-Bosiacka I Cells. 2023; 12(10).

PMID: 37408240 PMC: 10217339. DOI: 10.3390/cells12101406.

References

Agostini M, Janssen K, Kim I, DAngelo E, Pizzini S, Zangrando A . An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. Oncotarget. 2015; 6(32):32561-74. PMC: 4741712. DOI: 10.18632/oncotarget.4935. View

Li E, Yang X, Du Y, Wang G, Chan D, Wu D . CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer. Front Immunol. 2021; 12:667177. PMC: 8138166. DOI: 10.3389/fimmu.2021.667177. View

Cabrero-de Las Heras S, Martinez-Balibrea E . CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol. 2018; 24(42):4738-4749. PMC: 6235799. DOI: 10.3748/wjg.v24.i42.4738. View

Li C, Wang Z, Liu F, Zhu J, Yang L, Cai G . CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients. Tumour Biol. 2014; 35(10):9683-91. DOI: 10.1007/s13277-014-2234-0. View

Liao W, Overman M, Boutin A, Shang X, Zhao D, Dey P . KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019; 35(4):559-572.e7. PMC: 6467776. DOI: 10.1016/j.ccell.2019.02.008. View

Vandercappellen J, Van Damme J, Struyf S . The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008; 267(2):226-44. DOI: 10.1016/j.canlet.2008.04.050. View

Jamieson T, Clarke M, Steele C, Samuel M, Neumann J, Jung A . Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest. 2012; 122(9):3127-44. PMC: 3428079. DOI: 10.1172/JCI61067. View

Zeng J, Yang X, Cheng L, Liu R, Lei Y, Dong D . Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med. 2013; 11:6. PMC: 3551837. DOI: 10.1186/1479-5876-11-6. View

Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y . The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer. 2012; 132(2):276-87. DOI: 10.1002/ijc.27670. View

10.

Shen T, Yang Z, Cheng X, Xiao Y, Yu K, Cai X . CXCL8 induces epithelial-mesenchymal transition in colon cancer cells via the PI3K/Akt/NF-κB signaling pathway. Oncol Rep. 2017; 37(4):2095-2100. DOI: 10.3892/or.2017.5453. View

11.

Siegel R, Miller K, Sauer A, Fedewa S, Butterly L, Anderson J . Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020; 70(3):145-164. DOI: 10.3322/caac.21601. View

12.

Wu Z, Huang X, Han X, Li Z, Zhu Q, Yan J . The chemokine CXCL9 expression is associated with better prognosis for colorectal carcinoma patients. Biomed Pharmacother. 2016; 78:8-13. DOI: 10.1016/j.biopha.2015.12.021. View

13.

Chow M, Luster A . Chemokines in cancer. Cancer Immunol Res. 2014; 2(12):1125-31. PMC: 4258879. DOI: 10.1158/2326-6066.CIR-14-0160. View

14.

Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu C . Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer. 2017; 16(1):70. PMC: 5372323. DOI: 10.1186/s12943-017-0629-4. View

15.

Lin K, Zou R, Lin F, Zheng S, Shen X, Xue X . Expression and effect of CXCL14 in colorectal carcinoma. Mol Med Rep. 2014; 10(3):1561-8. DOI: 10.3892/mmr.2014.2343. View

16.

Zhang Y, Zheng S, Liao N, Huang H, Chen W, Wu Z . CircCTNNA1 acts as a ceRNA for miR-363-3p to facilitate the progression of colorectal cancer by promoting CXCL5 expression. J Biol Res (Thessalon). 2021; 28(1):7. PMC: 7913448. DOI: 10.1186/s40709-021-00135-8. View

17.

Li J, Liu Q, Huang X, Cai Y, Song L, Xie Q . Transcriptional Profiling Reveals the Regulatory Role of in Promoting Colorectal Cancer. Front Genet. 2020; 10:1360. PMC: 6985586. DOI: 10.3389/fgene.2019.01360. View

18.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

19.

Ruan G, Gong Y, Liao X, Wang S, Huang W, Wang X . Diagnostic and prognostic values of C‑X‑C motif chemokine ligand 3 in patients with colon cancer. Oncol Rep. 2019; 42(5):1996-2008. PMC: 6787997. DOI: 10.3892/or.2019.7326. View

20.

Balkwill F . Cancer and the chemokine network. Nat Rev Cancer. 2004; 4(7):540-50. DOI: 10.1038/nrc1388. View